Autoimmune disease and the environment. by unknown
NIEHS News
are there, Blumenthal said; it's just a matter
of knowing where and how to find them.
But Schardt defended the desire to repro-
duce such studies in U.S. labs, pointing out
that, for example, European studies on the
efficacy of St. John's wort for treating
depression average a length of only five
weeks-even though St. John's wort can
take as long as fourweeks to have anyeffect.
He also asserted that the results of certain
studies may not be as compelling as some
daim. For instance, in response to a claim
that some 28 controlled trials of various
forms ofechinacea have been conducted in
Europe, Schardt said that most of those
studies used parenteral echinacea, which is
not available in the United States, orpropri-
etary products that also are not available to
U.S. consumers. Furthermore, Schardt said,
the results ofseveral controlled trials testing
the effects oforal echinacea supplements on
the common cold and influenza are incon-
clusive. Still, there was general agreement
among the participants that the United
States must display more willingness to
cooperate with and participate in interna-
tional research on standardization, efficacy,
andsafety.
Financial support. Many speakers felt
that the money for testing, analyzing, and
evaluating the published safety and efficacy
data on medicinal herbs should come from
the government, and looked to the FDA as
the natural choice for initiating such studies.
But Yuan-Yuan Chiu, deputy director of
the Office of New Drug Chemistry at the
FDA Center for Drug Evaluation and
Research, claimed the agency has barely
enough resources to maintain the programs
already in place, and called on the other
government agencies represented to share
their funds and resources.
Others felt that industry bears the bur-
den of responsibility for supporting
research. Pharmaceutical companies rou-
tinely spend 10-20% of their profits on
research and development, a figure that is
not borne out in the botanical industry.
But, said Loren Israelsen, executive director
ofthe Utah Natural Products Alliance, con-
trary to an editorial in the 17 September
1998 issue of the New EnglandJournal of
Medicine in which editors Marcia Angell
and Jerome Kassirer suggest the botanical
industry is not interested in research, the
industry very much wants to conduct and
collaborate on botanicals research.
Israelsen described some of the dilem-
mas faced by the industry in terms of
research incentives versus expenditures. In
order to receive FDA approval as a nonpre-
scription drug, each substance within a
given plant-not just those within the
extract used in the botanical preparation-
would need to be studied in a lengthy,
expensive process. In addition, the FDA
review process for nonprescription drugs
does not allow consideration of foreign
data. Therefore, many studies that have
already been done overseas would need to
be duplicated.
Another issue is the Dietary Supplement
Health and Education Act of 1994, which
for the first time allowed botanical manu-
facturers to label their products with claims
ofhow the product may affect the structure
or functioning of the body. With the pas-
sage of the act, many manufacturers began
conducting legitimate research in order to
formulate their daims, but some manufac-
turers indulge in "borrowed science"-
applying the results of another company's
studies to their own products, often leading
to inaccurate daims (the resultant mislabel-
ing is addressed under the Federal Food,
Drug, and Cosmetic Act). Finally, most
synthetic drugs are developed with the goal
of being patented. But with the countless
varieties ofbotanical products being sold, it
is impossible to daim market exclusivity as a
research incentive.
BotanicalsToday ... andTomorrow
Research and regulatory decisions are much
too complex to base on a single workshop.
However, most participants seemed satisfied
to have been able to voice the concerns of
their particular camps, and excited about
the evident-albeit fragmented-wealth of
expertise represented at the workshop. A
summary of several recommendations
drawn from workshop presentations and
discussions is being compiled by the
NIEHS. Of the workshop, co-organizer
H.B. Matthews said, "We've certainly set
the stage for a continuing dialogue on this
subject."
According to Israelsen, a "broad under-
standing among all interested parties ofthe
issues involved" is needed. "We need to
serve the consumer, set aside animosities,
and just do the work," he said. "The real
[goal] is that the consumers have safe botan-
ical products.
Autoimmune Disease and the
Environment
According to a study published in the
September 1997 issue of Clinical
Immunology andImmunopathology by scien-
tists at The Johns Hopkins University in
Baltimore, Maryland, at least 10 million
people in the United States are affected by
one of 80 known autoimmune diseases.
These diseases include both organ-specific
conditions, such as type I diabetes, and sys-
tem-wide diseases, such as systemic lupus
erythematosus. They range from the well-
known, such as multiple sclerosis, to the rel-
atively rare and obscure, such as Takayasu's
arteritis (which attacks the aorta and its
branches). Perhaps because of the wide
range of the health effects caused by these
diseases, little is known about their origin
and epidemiology.
In an effort to address the dearth ofeti-
ologic information on this mysterious fami-
ly of diseases, a workshop entitled Linking
Environmental Agents and Autoimmune
Diseases was held 1-3 September 1998 at
the NIEHS campus in Research Triangle
Park, North Carolina. The workshop was
jointly sponsored by the NIEHS, the EPA
National Health and Environmental Effects
Research Laboratory (NHEERL), the NIH
Office ofRare Diseases, the NIH Office of
Research on Women's Health, the National
Institute ofAllergy and Infectious Disease,
the National Institute of Diabetes and
Digestive and Kidney Diseases, the
National Institute ofArthritis, Musculo-
skeletal, and Skin Diseases, the American
Autoimmune Related Diseases Association,
and theJuvenile Diabetes Foundation.
Almost all autoimmune diseases occur
more often in women than in men; in some
ofthese diseases, more than 90% ofpatients
are female. It is not clear exactly why
women are targeted more often than men,
but estrogen is suspected to play a pivotal
role. Autoimmune diseases seem to particu-
larly attack connective tissue and the neuro-
muscular, endocrine, and gastrointestinal
systems, but are not unknown in other parts
ofthe body.
Autoimmunity occurs when the body's
immune system turns against itself. The
immune system is designed to protect the
body by producing antibodies in response
to invading microorganisms such as viruses
or bacteria. Sometimes, for reasons that are
still not fully understood, these antibodies
are directed against self-, rather than for-
eign, antigens. Such a response probably
occurs naturally in most peop le to some
extent, but for someone with a genetic pre-
disposition to autoimmune disease, bacte-
ria, viruses, toxic agents, or certain drugs
may provide the boost necessary to trigger a
full-fledged autoimmune response. Other
factors that are believed to influence the
development of autoimmune disease
indude age, gender, and reproductive status
(e.g., pregnancy).
The workshop drew over 100 scientists
from a variety of disciplines, serving as a
forum for immunologists, developmental
biologists, autoimmune specialists, epidemi-
ologists, molecular biologists, and toxicolo-
gists to define the state ofthe science, iden-
tify data gaps, and map out the research still
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needed to fully understand the mechanistic
and causative links between environmental
agents and the various forms of autoim-
mune disease. Says Jerrold Heindel, a pro-
gram administrator in the NIEHS Organs
and Systems Toxicology Branch, "This was
the first time that this kind ofbroad group
ever got together [to discuss autoimmune
disease]." Heindel says the workshop
allowed for a stimulating exchange of ideas
and perspectives as representatives from
diverse fields compared their perceptions of
the problems that need to be addressed in
order to moveaheadwith research.
"A major aim of the workshop was to
look for common threads that would make
it easier to define the mechanism ofautoim-
mune diseases and the role ofenvironmen-
tal agents," says Heindel. "No significant
common threads were noted [at the work-
shop], which means that we still have to
examine each disease individually, which
makes for a much bigger problem. We still
hope that, as more data are accumulated,
common threads will appear."
Perhaps the most pressing need identi-
fied at theworkshop is for a nationwide sur-
veillance system to establish the occurrence
of autoimmune disease. Such a system
would also help identify clusters that might
be associated with a particular environmen-
tal exposure, cohorts forstudy, and suscepti-
ble populations. Dori Germolec, a group
leader of the NIEHS Environmental
Immunology Laboratory, says, "Many peo-
ple agreed we need a better nationwide reg-
istry for autoimmune diseases, both the spe-
cific diseases themselves and autoimmune
diseases as awhole."
Genetic factors have been shown to
play a role in the development of autoim-
mune diseases. For example, in a review
article published in the 3 May 1996 issue of
Cell, Timothy J. Vyse of the National
Jewish Center for Respiratory Medicine
and Immunology in Denver, (Iolorado,
and John A. Todd of the Wellcome Trust
Centre for Human Genetics in Oxford,
United Kingdom, used maps of markers
covering the mouse, rat, and human
genomes to identify 38 genes that predis-
pose humans and experimental animals to
autoimmune disorders. But, as Glinda
Cooper, an epidemiologist with the
NIEHS Environmental Diseases and
Medicine Program, pointed out at the
workshop, that does not negate the possible
role of environmental agents in the initia-
tion or exacerbation ofdisease. "It's not [a
matter of] 'genetics versus environment,"'
she says. "As researchers, our goal is to
understand the interaction between genes
and the environment."
A palette ofenvironmental factors have
been posited as possibly triggering various
autoimmune disorders. For instance, expo-
sure to chemicals such as dioxins and poly-
chlorinated biphenyls has been linked with
non-Hodgkin's lymphoma, while certain
dietary factors seem to contribute to type 1
diabetes. Other environmental suspects
include ultraviolet radiation (multiple scle-
rosis), cross-reactivity with environmental
antigens (type 1 diabetes), ionizing radiation
(systemic lupus erythematosus), stress
(rheumatoid arthritis), and exposure to
heavy metals such as lead and mercury
(autoimmune glomerulonephritis).
There is also a need, said workshop par-
ticipants, to develop and identify research
tools such as biomarkers ofdisease that are
amenable to both animal andhuman studies,
questionnaires for epidemiologic and clinical
tests, and testing strategies to screen chemi-
cals for the potential to initiate or exacerbate
autoimmune disease. In an artide published
in the March 1995 issue of Immunology
Today, Argyrios N. Theofilopoulos, an
immunologist at the Scripps Research
Institute in La Jolla, California, predicted
that "the definition of[autoimmune] diseases
is about to be revolutionized by the develop-
ment of genome scanning approaches, such
as dense chromosomal maps based on poly-
morphic microsatellite DNAandotherinfor-
mative markers."
The findings ofthe breakout groups will
be compiled into a list of research recom-
mendations that will be distributed to NIH
institutes, interested foundations, and the
research community. Says Mary Jane
Selgrade, chief of the Immunotoxicology
Branch at the NHEERL, "It is our hope
that the data gaps and needs the workshop
participants have identified will stimulate
research into the next decade."
w
Talk of the Towns
In the beliefthat dialogue is thefirststep to resolvingthe environmental problems soci-
ety currently faces, the NIEHS has instituted a series ofregional town meetings to be
hosted byvarious NIEHS Environmental Health Sciences Centers. These meetings are
aimed at giving a voice to the myriad groups (including local, state, and federal health
officials, policy makers, academicians, and members of the community) interested in
publichealth and the environment.
The first town meeting was held 17-18 September 1998 and was hosted by the
Environmental and Occupational Health Sciences Institute, a program of the
University ofMedicine and Dentistry ofNew Jersey-Robert Wood Johnson Medical
School and Rutgers University. This event set the goals for the planned series oftown
meetings. The primary goal is to provide a platform for open dialogue to encourage
better coordination among the health professionals working on community exposures,
industrial exposures and pesticides, site-specific exposures and cluster issues, and other
environmental issues that impact human health. A secondary goal is to promote local
and state mediacoverage ofenvironmental health to broadenpublicunderstanding.
Three more town meetings (listed below) are currently scheduled around the
United States, andmore are planned for later in 1999.
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